Teva cut its adjusting earnings-per-share guidance for the year. "Teva Revenue Rises on Allergan Deal, But Its Specialty Drugs Saw Pressure," at 8:10 a.m. ET, incorrectly stated that it had raised its guidance in the fourth paragraph.
(END) Dow Jones Newswires
November 15, 2016 09:44 ET (14:44 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.